Skip to content
Search

Latest Stories

RPS to train foundation trainee pharmacists in Northern Ireland

The Royal Pharmaceutical Society (RPS) will provide clinical training and registration assessment support to foundation trainee pharmacists  in Northern Ireland.

Under the newly awarded contract, RPS will deliver an education and training programme comprising the clinical elements of the Northern Ireland Centre for Pharmacy Learning and Development (NICPLD) training programme from July.


It will also conduct a half and full mock exam with in-depth feedback.

The programme will benefit 143 trainees, preparing for the Common Registration Assessment (CRA) 2022.

“It is fantastic news that we have been offered this training contract to help shape Northern Ireland’s pharmacists of tomorrow,” said Gail Fleming, RPS director of education and professional development.

The RPS has been running a comprehensive programme of pre-registration revision and support since 2012 for trainees in England, Scotland and Wales.

Colin Adair, postgraduate pharmacy dean at NICPLD, said: “We have collaborated with the RPS over many years, and are particularly pleased to be able to formalise our relationship with this new contract to support trainees preparing for the CRA.”

“The RPS has a fantastic reputation for supporting the profession and we look forward to working with them during this critical phase for pharmacy as we transition to the foundation training year and beyond that to advanced and consultant practice,” Adair added.

More For You

Walgreens Boots Alliance acquired by Sycamore in deal

Walgreens Boots Alliancehas entered into “a definitive agreement” to be acquired by Sycamore Partners

Gettyimages

Walgreens Boots Alliance acquired by Sycamore in £18.3 billion deal

Walgreens Boots Alliance(WBA) has entered into “a definitive agreement” to be acquired by Sycamore Partners, a private equity firm specializing in retail, consumer and distribution-related investments.

“The total value of the transaction represents up to $23.7 billion (£18.3 billion),” the company announced late last night (6).

Keep ReadingShow less
Professor Sir Stephen Powis at a press briefing

Professor Sir Stephen Powis, was appointed national medical director of NHS England in 2018

NHS

NHS England’s top doctor to step down following Amanda Pritchard’s resignation

Just a week after NHS England chief executive Amanda Pritchard announced her resignation, the organisation’s national medical director, Professor Sir Stephen Powis, has confirmed he will step down this summer after more than seven years in the role.

In a statement released on Thursday, Professor Powis revealed that he had informed Pritchard of his intention to leave in a letter back in January.

Keep ReadingShow less
PDA calls on GP practices to use funding boost to improve job security for pharmacists

Now, it is time to focus on the community pharmacy contract

gettyimages

PDA urges GP practices to ensure funding boost supports employed pharmacists

The Pharmacists' Defence Association (PDA) has called on GP practicesto ensure that all healthcare professionals they employ, including pharmacists, benefit from the 7.2% funding boost they received under a newly agreed contract.

GP employers are encouraged to improve “job security, pay and conditions” for employees with this increased funding.

Keep ReadingShow less
Fourth Shift: Investment in Innovative Medicines Crucial for NHS 10-Year Plan Success

Medicines should be viewed as an investment rather than a cost

gettyimages

ABPI wants to see a ‘fourth shift’ in NHS 10-Year Health Plan


The Association of the British Pharmaceutical Industry (ABPI) has called on the government to increase investment in innovative medicines and vaccines, describing it as a crucial “fourth shift” necessary to ensure the NHS is fit for the future.

Keep ReadingShow less
Lawrence Tallon named new MHRA chief executive

Lawrence Tallon

Photo credit: Sciana Network

Lawrence Tallon named new MHRA chief executive

Lawrence Tallon has been appointed as the new chief executive officer of the Medicines and Healthcare products Regulatory Agency (MHRA), effective 1 April 2025.

He will succeed Dame June Raine DBE, who is retiring after leading the agency since 2019.

Keep ReadingShow less